The patent cliff isn’t just a legal event—it’s a payer strategy deadline.
Most teams treat the “patent cliff” like a countdown to generic entry. But in payer-land, the clock starts earlier—and the winners aren’t always the ones with the best science. T…
Beat the Patent Cliff: How to Trigger Payer Strategy Campaigns Before Drug Patent LOE Read Post »
ð¨ The drug patent cliff just got a new kind of pressure test.
OpenAI’s GPT—paired with Rosalind’s scientific workflow—has reportedly been used to “smash” some of the most stubborn drug patent cliffs, with claims of ~70% faster development cycles f…
OpenAI’s GPT-Rosalind = Smashed Drug Patent Cliffs and 70% Faster ANDAs Read Post »
Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive with a press release. They arrive quietly—months before launch—inside the legal and regulatory machiner…
Your drug’s “patent life” isn’t one number in the GCC. It’s a moving target. Here’s how to know exactly what you’re really buying.
If you’re a brand team, investor, or in-house counsel working on the Gulf Cooperation Council (GCC), you already know the…
Know Exactly How Long Your Drug Patent Lasts in the GCC Read Post »
Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…
Know Exactly How Long Your Drug Patent Lasts in the GCC Read Post »
Your competitor isn’t just “improving” a drug. They’re often extending its life—quietly, legally, and with a paper trail you can read.
Here are four signals—straight from the patent playbook—that a company may be preparing to delay generic entry or ext…
Read the Patent Trail: 4 Signals Your Competitor Is Extending a Drug’s Life Read Post »
Biopharma teams don’t lose deals because they lack ambition—they lose because they mis-time the pitch.
In licensing, partnerships, and BD strategy, timing is everything. But too often, the “when” is treated like a calendar exercise rather than a commer…
OpenAI’s “GPT for life sciences” is getting the hype cycle treatment. But the real question for drug developers isn’t whether the model can sound smart—it’s whether it can change the economics of discovery.
That’s the tension at the heart of the discus…
GPT-Rosalind: What OpenAI’s Life Sciences Model Actually Does to Drug Development Read Post »
Fatigue is a common side effect of Lipitor, a medication used to lower cholesterol levels and prevent heart disease. According… https://www.Drugchatter.com/chat/16688/do-you-often-feel-tired-after-taking-lipitor/
DrugChatter: Do you often feel tired after taking lipitor? Read Post »
Most biosimilar strategies fail for one reason: they show up too late.
In biosimilars, timing isn’t a detail—it’s the business model.
Patent expiry intelligence is often treated like a calendar tool: identify the likely “go-live” date, plan a launch, a…
Get new actionable insights and updates from BiotechBlog
